N-Acetyl Semax

Specifications N-Acetyl Semax

Company: Hilma Biocare
Group: Injection/powder
Active Half-life (min): 2 to 5
Subgroup: Peptide hormone
Dosage: 50 mg
Application (Men): 0,1-4 mg, depending on the treatment plan
Product pack:  1 vial
Content (active): N-Acetyl Semax
Retains water: No
Aromatization: No

DESCRIPTION

N-Acetyl Semax is a synthetic neuropeptide, an analogue of a fragment of adrenocorticotropic hormone (ACTH 4-10), but completely devoid of hormonal activity. It belongs to the class of regulatory peptides and exhibits nootropic, stimulating, neuroprotective, antioxidant, and antihypoxic effects. It helps improve mental and physical performance.

This product is a modified, more stable and bioavailable form of the nootropic peptide Semax. Unlike the standard Semax peptide, the addition of an acetyl group increases the half-life and effectiveness of the drug, allowing for lower dosages to achieve results.

In some countries, N-Acetyl Semax is listed as a vital and essential drug.

INDICATIONS

N-Acetyl Semax is used medically for the treatment of stroke, transient ischemic attack, memory and cognitive impairment, gastric ulcers, optic nerve disorders, and for strengthening the immune system.

The drug exhibits the following properties:
● Increased concentration, improved memory, and improved learning;
● Brain stimulation: increased levels of brain-derived neurotrophic factor (BDNF);
● Neuroprotection: protection of neurons during stress and ischemia (oxygen deficiency);
● Accelerated rehabilitation after brain injuries and strokes.

APPLICATION

Various routes of administration are permitted: intranasal (nasal drops) for rapid penetration across the blood-brain barrier (within 4 minutes) or subcutaneous administration into fatty tissue (usually in the abdominal area).

DOSAGE

The dosage is determined individually, depending on the goal of therapy. Studies have shown the effectiveness of the following dosage regimens.
Mental fatigue: 0.1–0.3 mg 1–3 times daily for 3–7 days.
Optic nerve atrophy: 0.3 mg 1–3 times daily for 7–10 days. This dosage is highly effective when extended for up to 30 days if necessary.
Cognitive impairment associated with encephalopathy and cerebrovascular accidents: up to 2 mg 2–4 times daily for 10–14 days. The course may be repeated if necessary.
Traumatic brain injury: 1–3.5 mg 3 times daily for 3–5 days. The course may be extended to 14 days if necessary.
Moderate stroke: 2–3 mg 3–4 times daily with 3–4 hours between doses for 10 days. The course may be repeated if necessary after a 20-day break.
Severe stroke: 3–4 mg 4–6 times daily with an interval of 2.5–3 hours between doses for 10 days.

Studies have also shown the effectiveness of prophylactic courses for moderate nervous exhaustion at a dose of 0.2–0.5 mg 1–2 times daily for up to 30 days.

The dosage and duration of treatment are adjusted by the attending physician based on the patient’s individual response.

CONTRAINDICATIONS

● Hypersensitivity to any of the components of the drug;
● Pregnancy;
● Lactation;
● Acute psychosis;
● Anxiety disorders;
● History of seizures;
● Children under 5 years of age.

DRUG INTERACTIONS

For reasons of caution, it is not recommended to combine this medication with other stimulants or nootropic agents.

SIDE EFFECTS

When used correctly, side effects are rare. During clinical trials, a small number of patients experienced mild discomfort in the nasopharynx with intranasal administration or mild swelling at the injection site. This is more likely due to inadequate sterile technique than a reaction to the drug.